STOCK TITAN

Ambrx Biopharma Inc - AMAM STOCK NEWS

Welcome to our dedicated page for Ambrx Biopharma news (Ticker: AMAM), a resource for investors and traders seeking the latest updates and insights on Ambrx Biopharma stock.

Ambrx Biopharma Inc. (NASDAQ: AMAM) is a clinical-stage biotechnology pioneer developing precision antibody-drug conjugates (ADCs) for oncology through its proprietary protein engineering platform. This page serves as the definitive source for AMAM news, providing investors and researchers with timely updates on clinical developments, corporate milestones, and therapeutic innovations.

Access consolidated updates on AMAM's ADC pipeline progress, including Phase 1/2 trials for ARX517 (PSMA-targeting prostate cancer therapy) and ARX788 (HER2-positive cancer treatment). Track strategic partnerships, regulatory filings, and financial disclosures that impact the company's trajectory in the competitive biopharma sector.

Our news collection features verified press releases on clinical trial results, manufacturing advancements, and intellectual property developments. Stay informed about AMAM's expanded genetic code technology applications and their implications for next-generation cancer therapeutics.

Bookmark this page for streamlined access to material events affecting AMAM's market position. Check regularly for updates on ADC platform innovations, peer-reviewed research publications, and executive leadership announcements from this oncology-focused biotech innovator.

Rhea-AI Summary

Cartography Biosciences has appointed Troy E. Wilson, Ph.D., J.D. as an independent director to its Board of Directors. Wilson, a 25-year biopharma industry veteran, is currently President, CEO, and co-founder of Kura Oncology (NASDAQ: KURA). He brings extensive experience in founding and leading biotech companies, including Avidity Biosciences, Araxes Pharma, and Wellspring Biosciences. Cartography, an oncology company developing antibody therapeutics, aims to leverage Wilson's expertise as it advances its pipeline of novel programs targeting tumors more precisely than existing treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary
Ambrx Biopharma, Inc. shareholders approved a merger agreement with Johnson & Johnson, with shareholders set to receive $28.00 per share in cash. The CEO highlighted the company's focus on protein engineering innovation and promising pipeline for cancer treatments. Over 99% of votes were in favor of the merger, signaling strong shareholder support.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.07%
Tags
-
Rhea-AI Summary
Ambrx Biopharma, Inc. (AMAM) has entered into a definitive agreement with Johnson & Johnson for acquisition at $28.00 per share in cash, representing an approximately 105% premium to Ambrx’s closing stock price on January 5, 2024, for a total equity value of approximately $2.0 billion. The acquisition aims to advance scientific research to treat cancers with high unmet needs. Ambrx's proprietary Antibody Drug Conjugate (ADC) technology and leading prostate cancer candidate are key highlights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
101.54%
Tags
none
Rhea-AI Summary
Johnson & Johnson (JNJ) strengthens its commitment to oncology innovation by acquiring Ambrx Biopharma, Inc. (AMAM) in an all-cash merger transaction for approximately $2.0 billion. Ambrx's clinical and preclinical programs, including lead product candidate ARX517, a prostate-specific membrane antigen (PSMA)-targeting antibody drug conjugate (ADC), align with J&J's goal of developing next-generation ADCs and targeted oncologic therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Ambrx Biopharma, Inc. (AMAM) will be added to the NASDAQ Biotechnology Index (NBI), effective December 18, 2023. This follows a transformational year for Ambrx, including voluntarily transferring to Nasdaq from the New York Stock Exchange, changing parent company domicile to Delaware, and terminating the ADS program. CEO Daniel J. O’Connor believes these changes may enhance long-term shareholder value and increase the company's profile in the investment community.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.51%
Tags
none
-
Rhea-AI Summary
Ambrx Biopharma, Inc. (AMAM) announced positive clinical results for its anti-PSMA antibody drug conjugate ARX517 in the APEX-01 trial for metastatic castration-resistant prostate cancer. Cohort 9 showed no dose limiting toxicities or serious adverse events, with two patients experiencing rapid PSA reduction after one dose. Cohort 8 is fully enrolled, and the recommended phase 2 dose is expected by early next year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.94%
Tags
Rhea-AI Summary
Ambrx Biopharma announces positive results from Phase 1 portion of APEX-01 trial for ARX517 in metastatic castration-resistant prostate cancer (mCRPC)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
none
-
Rhea-AI Summary
Ambrx Biopharma Inc. will host an in-person key opinion leader event during the ESMO Congress 2023, featuring preliminary data from APEX-01 study on ARX517 in prostate cancer patients. Virtual webcast and presentation materials will be available for those unable to attend.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.4%
Tags
conferences
-
Rhea-AI Summary
Ambrx CEO participates in fireside chat and one-on-one meetings at Cantor Fitzgerald Global Healthcare conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.22%
Tags
conferences
Rhea-AI Summary
Ambrx Biopharma CEO to present at healthcare conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.64%
Tags
conferences
Ambrx Biopharma Inc

Nasdaq:AMAM

AMAM Rankings

AMAM Stock Data

1.77B
61.65M
2.1%
103.43%
1.83%
Biotechnology
Healthcare
Link
United States
La Jolla